Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential.
Curr Pharm Biotechnol
January 2025
Center for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA.
The SARS-CoV-2 pandemic has highlighted the need for society, as a whole, to be prepared against potential pandemics caused by a variety of different viral families of concern. Here, we describe a roadmap towards the identification and validation of conserved T cell epitope regions from Viral Families of Pandemic Potential (VFPP). For each viral family, we select a prototype virus, the sequence of which could be utilized in epitope identification screens.
View Article and Find Full Text PDFConformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates.
bioRxiv
November 2024
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037 USA.
Lassa virus (LASV), an arenavirus endemic to West Africa, poses a significant public health threat due to its high pathogenicity and expanding geographic risk zone. LASV glycoprotein complex (GPC) is the only known target of neutralizing antibodies, but its inherent metastability and conformational flexibility have hindered the development of GPC-based vaccines. We employed a variant of AlphaFold2 (AF2), called subsampled AF2, to generate diverse structures of LASV GPC that capture an array of potential conformational states using MSA subsampling and dropout layers.
View Article and Find Full Text PDFDiscovering Lassa virus nucleoprotein inhibitors via in silico drug repositioning approach.
J Biomol Struct Dyn
November 2024
Department of Biology Biotechnology Division, Istanbul University, Istanbul, Turkey.
Lassa fever, caused by the zoonotic Lassa virus (LASV), poses a significant health threat in Africa, leading to thousands of infections and deaths annually and has the potential to spread to other parts of the world. Despite the urgency for effective treatments, there are currently no approved drugs or vaccines for Lassa fever. LASV possesses a unique negative-sense RNA genome, and NP plays a crucial role in viral assembly and infection.
View Article and Find Full Text PDFLassa virus (LASV) outbreaks in West Africa pose a significant public health threat. We investigated the infection phenotype and transmission (horizontal and vertical) of LASV strain Ba366 in its natural host, Mastomys natalensis. Here we analyze viral RNA levels in body fluids, virus titers in organs and antibody presence in blood.
View Article and Find Full Text PDFCoadministration of LHF-535 and favipiravir protects against experimental Junín virus infection and disease.
Antiviral Res
September 2024
Institute for Antiviral Research, Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA. Electronic address:
Article Synopsis
- - Argentine hemorrhagic fever, caused by the Junín virus (JUNV), has a high mortality rate and currently relies on limited treatments like immune plasma, highlighting the need for new antiviral therapies.
- - The fusion inhibitor LHF-535 and nucleoside analog favipiravir have shown potential in combating arenaviral infections, but using favipiravir alone requires high doses for effectiveness against JUNV.
- - Combining LHF-535 with a lower dose of favipiravir in guinea pig models resulted in complete protection from JUNV, demonstrating the potential of this drug combination to broaden treatment options and prevent drug resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!